Navigation Links
DURECT Corporation to Participate in Upcoming Healthcare Conferences
Date:8/31/2011

CUPERTINO, Calif., Aug. 31, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at three upcoming healthcare conferences.

(Logo:  http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

  • Jim Brown, President and CEO, will present at the Stifel Nicolaus Healthcare Conference in Boston on Thursday, September 8 at 3:50 p.m. Eastern Time. A live audio webcast of the presentation will be available by accessing http://www.veracast.com/webcasts/stifel/healthcare2011/19213681.cfm.
  • Matt Hogan, Chief Financial Officer, will present at the Rodman & Renshaw Life Sciences Conference in New York on Monday, September 12 at 10:40 a.m. Eastern Time.  A live audio webcast of the presentation will be available by accessing http://www.wsw.com/webcast/rrshq20/drrx .
  • Matt Hogan will also present at the UBS Global Life Sciences Conference in New York on Monday, September 19 at 3:00 p.m. Eastern Time.  A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR®, ELADUR™ and DURIN® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
4. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
5. DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
6. DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference Call
7. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
8. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
9. DURECT to Present at the Cowen and Company Healthcare Conference
10. DURECT to Present at the Barclays Capital Global Healthcare Conference
11. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... July 20, 2017  Prime Therapeutics LLC (Prime) released this ... M.D., following today,s Institute for Clinical and Economic Review,s (ICER) ... the effectiveness and value of abuse-deterrent formulations (ADF) of opioids. ... roundtable at the meeting. ... cost benefit to the use of abuse-deterrent formulations (ADF) in ...
(Date:7/17/2017)... Fla. , July 17, 2017  MedX Holdings, ... branded medical testing, strengthening and rehabilitation equipment, today announced ... Machine Program. MedX is considered the gold standard for ... leader in specialized medical strengthening equipment. ... a lease with the physician or practice who prescribe ...
(Date:7/14/2017)... DUBLIN , July 14, 2017 Endo International plc ... results on Tuesday, August 8, 2017.  Members of its senior management ... financial markets open at 8:30 a.m. ET. The ... (866) 497-0462, International (678) 509-7598, and the passcode is 45397076. ... A replay of the ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... ... and financial planning services to families and business owners in northern Florida, is ... promises to provide support to area adults with developmental challenges. , The First ...
(Date:7/21/2017)... Grove, Ill. (PRWEB) , ... July 21, 2017 , ... ... & Fabric Liquid eco-friendly odor-control solution for colleges and universities at the ... safely and effectively eliminate severe cannabis and tobacco smoke odors without the use of ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, 2017 , ... ... Chicago, IL and Past President of the American Orthopaedic Society of Sports Medicine ... July 21, 2017 during the AOSSM Annual Meeting in Toronto, Canada. This prestigious award ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... has received a $5,000 grant from the C. R. Bard Foundation, Inc. ... Center at Somerset Hills , a service available through the nonprofit home care ...
(Date:7/21/2017)... ... 21, 2017 , ... Sharon Kleyne is proud of the ... research center at Bio-Logic Aqua Research® Water Life Science®, has been released in ... sufferers of blindness. “We think that Nature’s Tears® EyeMist® will contribute to eliminating ...
Breaking Medicine News(10 mins):